- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT01292226
A Study of the Correlation Between Pharmacokinetic and Pharmacodynamic Parameters of CellCept (Mycophenolate Mofetil).
8 kwietnia 2016 zaktualizowane przez: Hoffmann-La Roche
Relationships Between Pharmacokinetic and Pharmacodynamic Strategies for Assessment of the Risks for Acute Rejection and Side Effects of Mycophenolate Mofetil
This study will evaluate the correlation between the pharmacokinetic and pharmacodynamic parameters of CellCept in patients undergoing primary kidney transplantation, in order to assess the impact on clinical outcome and the risks of acute rejection.
All patients will receive oral CellCept, 1g twice daily, and pharmacokinetic and pharmacodynamic parameters will be measured at weeks 2, 4, 12 and 24.
The anticipated time on study treatment is 24 weeks.
Przegląd badań
Status
Zakończony
Warunki
Interwencja / Leczenie
Typ studiów
Interwencyjne
Zapisy (Rzeczywisty)
45
Faza
- Faza 2
Kontakty i lokalizacje
Ta sekcja zawiera dane kontaktowe osób prowadzących badanie oraz informacje o tym, gdzie badanie jest przeprowadzane.
Lokalizacje studiów
-
-
-
Bari, Włochy, 70124
-
Brescia, Włochy, 25123
-
Coppito, Włochy, 67100
-
Napoli, Włochy, 80131
-
Roma, Włochy, 00168
-
Torino, Włochy, 10126
-
Verona, Włochy, 37126
-
-
Kryteria uczestnictwa
Badacze szukają osób, które pasują do określonego opisu, zwanego kryteriami kwalifikacyjnymi. Niektóre przykłady tych kryteriów to ogólny stan zdrowia danej osoby lub wcześniejsze leczenie.
Kryteria kwalifikacji
Wiek uprawniający do nauki
18 lat do 65 lat (Dorosły, Starszy dorosły)
Akceptuje zdrowych ochotników
Nie
Płeć kwalifikująca się do nauki
Wszystko
Opis
Inclusion Criteria:
- Adult patients, 18 to 65 years of age
- Patients undergoing primary kidney transplantation
Exclusion Criteria:
- Recipients of multiple organ transplants
- Prior therapy with CellCept
- Presence or history of malignancies, except for successfully treated basal or squamous cell carcinoma of the skin
- Active peptic ulcer or active serious digestive system disease that may affect the absorption of CellCept
Plan studiów
Ta sekcja zawiera szczegółowe informacje na temat planu badania, w tym sposób zaprojektowania badania i jego pomiary.
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Leczenie
- Przydział: Nie dotyczy
- Model interwencyjny: Zadanie dla jednej grupy
- Maskowanie: Brak (otwarta etykieta)
Broń i interwencje
Grupa uczestników / Arm |
Interwencja / Leczenie |
---|---|
Eksperymentalny: Mycophenolate Mofetil Monotherapy
Participants received an initial dose of mycophenolate mofetil (MMF), 1 gram (g), orally (PO), twice per day (BID), within 5 days of transplant for 24 weeks.
Participants also received concurrent antibody induction, cyclosporine, and corticosteroids as needed according to center's practice.
|
1 g PO BID for 24 weeks
Inne nazwy:
According to manufacturer recommendation
According to manufacturer recommendation
According to manufacturer recommendation
|
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
---|---|---|
Percentage of Participants With Acute Rejection
Ramy czasowe: Day 1, Weeks 2, 4, 12, 24, and 28
|
Diagnosis of acute rejection was suspected in any participant with an increase in serum creatinine greater than or equal to (≥) 25 percent (%).
All suspected acute rejections were confirmed by biopsy.
The start date of acute rejection was identified as the date of biopsy.
|
Day 1, Weeks 2, 4, 12, 24, and 28
|
Time to Rejection
Ramy czasowe: Day 1, Weeks 2, 4, 12, 24, and 28
|
The mean time, in days, from the date of enrollment to date of biopsy confirming acute rejection.
|
Day 1, Weeks 2, 4, 12, 24, and 28
|
Percentage of Participants With Biopsy-Proven Acute Rejection (BPAR)
Ramy czasowe: Day 1, Weeks 2, 4, 12, 24, and 28
|
BPAR was defined according to 1997 Banff Criteria as a biopsy Banff grade of IA, IB, IIA, IIB, or III.
Grade IA was defined as significant interstitial infiltration with greater than (>)25% of parenchyma affected, and foci of moderate tubulitis with >4 mononuclear cells per tubular cross section or group of 10 tubular cells.
Grade IB was defined as significant interstitial infiltration with >25% parenchyma affected, and foci of severe tubulitis with >10% mononuclear cells per tubular cross section or group of 10 tubular cells.
Grade IIA was defined as mild to moderate intimal arteritis.
Grade IIB was defined as severe intimal arteritis comprising >25% of the luminal area.
Grade III was defined as transmural arteritis and/or arterial fibrinoid changes and necrosis of medial smooth muscle cells.
|
Day 1, Weeks 2, 4, 12, 24, and 28
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
---|---|---|
Percentage of Participants With Graft Loss
Ramy czasowe: Day 1, Weeks 2, 4, 12, 24, and 28
|
An allograft was presumed to be lost if a participant started dialysis and was not able to subsequently be removed from dialysis.
|
Day 1, Weeks 2, 4, 12, 24, and 28
|
Percentage of Participants Surviving
Ramy czasowe: Day 1, Weeks 2, 4, 12, 24, and 28
|
Day 1, Weeks 2, 4, 12, 24, and 28
|
|
Total Mycophenolate Acid (MPA) by Visit and Timepoint
Ramy czasowe: Weeks 2, 4, 12, 24, and 28 (Safety Follow-Up Visit), and any unscheduled visits
|
Drug quantification of total MPA (micrograms per milliliter [mcg/mL]) in the plasma was measured at time (T) = 0 minutes (min), 40 mins, and 120 mins.
|
Weeks 2, 4, 12, 24, and 28 (Safety Follow-Up Visit), and any unscheduled visits
|
Free MPA (mcg/mL) by Visit
Ramy czasowe: Weeks 2, 4, 12, 24, safety follow-up (Week 28), and any unscheduled visits
|
Drug quantification of free MPA in the plasma was measured at T = 0, 40, and 120 mins.
|
Weeks 2, 4, 12, 24, safety follow-up (Week 28), and any unscheduled visits
|
MPA Area Under the Concentration - Time Curve From Time 0 to 12 Hours (AUC0-12) (mcg/mL) by Visit
Ramy czasowe: Predose and 40 minutes and 2 hours postdose at Weeks 2, 4, 12, and 24, and at the Safety follow-up (Week 28)
|
The AUC0-12 of MPA was estimated on the validated limited sampling strategy, AUC (milligrams multiplied by height over liter [mg.h/L]) = 7.182 + 4.607 multiplied by (*) concentration at 0 minutes (C0)+ 0.998 * the concentration at 40 minutes (C0.67) + 2.149 * the concentration at 120 minutes (C2).
|
Predose and 40 minutes and 2 hours postdose at Weeks 2, 4, 12, and 24, and at the Safety follow-up (Week 28)
|
Inosine MonoPhosphate DeHydrogenase (IMPDH) Activity by Visit and Timepoint
Ramy czasowe: BL and Weeks 2, 4, 12, and 24, and safety follow-up (Week 28) and any unscheduled visits
|
IMPDH activity in peripheral blood mononuclear cells (PBMCs) was measured at 2 timepoints per visit, 0 and 120 minutes and presented in enzyme units.
The unit of measure of enzyme activity is "U".
One U is defined as the amount of the enzyme that produces a certain amount of enzymatic activity that is, the amount that catalyzes the conversion of 1 micro mole of substrate per minute under pre-specified conditions (temperature, pH).
|
BL and Weeks 2, 4, 12, and 24, and safety follow-up (Week 28) and any unscheduled visits
|
IMPDH Expression I by Visit and Timepoint
Ramy czasowe: BL and Weeks 2, 4, 12, and 24, and safety follow-up (Week 28) and any unscheduled visits
|
IMPDH I gene expression was measured by real time polymerase chain reaction (QRT-PCR) based cytokine measurement of PBMCs at 2 timepoints per visit, 0 and 120 minutes and expressed as number of messenger ribonucleic acid (mRNA) copies per cell (copies/cell).
|
BL and Weeks 2, 4, 12, and 24, and safety follow-up (Week 28) and any unscheduled visits
|
IMPDH Expression II by Visit and Timepoint
Ramy czasowe: BL and Weeks 2, 4, 12, and 24, and safety follow-up (Week 28) and any unscheduled visits
|
IMPDH II gene expression was measured by QRT-PCR based cytokine measurement of PBMCs at 2 timepoints per visit, 0 and 120 minutes and expressed as number of mRNA copies/cell.
|
BL and Weeks 2, 4, 12, and 24, and safety follow-up (Week 28) and any unscheduled visits
|
Interleukin 8 (IL-8) Expression by Visit and Timepoint
Ramy czasowe: BL and Weeks 2, 4, 12, and 24, and safety follow-up (Week 28) and any unscheduled visits
|
IL-8 gene expression was measured by QRT-PCR based cytokine measurement of PBMCs at 2 timepoints per visit, 0 and 120 minutes and expressed as number of mRNA copies/cell.
|
BL and Weeks 2, 4, 12, and 24, and safety follow-up (Week 28) and any unscheduled visits
|
Tumor Necrosis Factor (TNF) Expression by Visit and Timepoint
Ramy czasowe: BL and Weeks 2, 4, 12, and 24, and safety follow-up (Week 28) and any unscheduled visits
|
TNF gene expression was measured by QRT-PCR based cytokine measurement of PBMCs at 2 timepoints per visit, 0 and 120 minutes and expressed as number of mRNA copies/cell.
|
BL and Weeks 2, 4, 12, and 24, and safety follow-up (Week 28) and any unscheduled visits
|
Percentage of Participants With Infection
Ramy czasowe: BL and Weeks 2, 4, 12, 24, and 28 (Safety Follow-Up)
|
Infections were graded according to the World Health Organization (WHO) worst grade observed.
|
BL and Weeks 2, 4, 12, 24, and 28 (Safety Follow-Up)
|
Percentage of Participants With Gastrointestinal Toxicities
Ramy czasowe: BL and Weeks 2, 4, 12, 24, and 28 (Safety Follow-up Visit)
|
Gastrointestinal adverse events (AEs) according to WHO worst grade observed.
|
BL and Weeks 2, 4, 12, 24, and 28 (Safety Follow-up Visit)
|
Percentage of Participants With Hematologic Toxicity
Ramy czasowe: BL and Weeks 2, 4, 12, 24, and 28 (Safety Follow-Up)
|
Hematological toxicities graded according to WHO worst grade observed (Grade 1=mild, Grade 2=moderate).
|
BL and Weeks 2, 4, 12, 24, and 28 (Safety Follow-Up)
|
Spearman's Rank Correlation Coefficient Between MPA Levels and IMPDH Activity
Ramy czasowe: BL and Weeks 2, 4, 12, and 24
|
The Spearman's rank correlation coefficient was computed by ranking the data from 2 time points, 0 minutes and 120 minutes, and using the ranks in the Pearson product-moment correlation formula.
In case of ties, the averaged ranks were used.
|
BL and Weeks 2, 4, 12, and 24
|
Spearman's Rank Correlation Coefficient Between IMPDH I Expression and MPA Levels
Ramy czasowe: BL and Weeks 2, 4, 12, and 24
|
The Spearman's rank correlation coefficient was computed by ranking the data from 2 time points, 0 minutes and 120 minutes, and using the ranks in the Pearson product-moment correlation formula.
In case of ties, the averaged ranks were used.
|
BL and Weeks 2, 4, 12, and 24
|
Spearman's Rank Correlation Coefficient Between IMPDH I Expression and Free Fraction
Ramy czasowe: BL and Weeks 2, 4, 12, and 24
|
The Spearman's rank correlation coefficient was computed by ranking the data from 2 time points, 0 minutes and 120 minutes, and using the ranks in the Pearson product-moment correlation formula.
In case of ties, the averaged ranks were used.
|
BL and Weeks 2, 4, 12, and 24
|
Spearman's Rank Correlation Coefficient Between IMPDH II Expression and MPA Levels
Ramy czasowe: BL and Weeks 2, 4, 12, and 24
|
The Spearman's rank correlation coefficient was computed by ranking the data from 2 time points, 0 minutes and 120 minutes, and using the ranks in the Pearson product-moment correlation formula.
In case of ties, the averaged ranks were used.
|
BL and Weeks 2, 4, 12, and 24
|
Spearman's Rank Correlation Coefficient Between IMPDH II Expression and Free Fraction
Ramy czasowe: BL and Weeks 2, 4, 12, and 24
|
The Spearman's rank correlation coefficient was computed by ranking the data from 2 time points, 0 minutes and 120 minutes, and using the ranks in the Pearson product-moment correlation formula.
In case of ties, the averaged ranks were used.
|
BL and Weeks 2, 4, 12, and 24
|
Spearman's Rank Correlation Coefficient Between IMPDH Inhibition and Risk of Acute Rejection
Ramy czasowe: BL and Weeks 2, 4, 12, and 24
|
The Spearman's rank correlation coefficient was computed by ranking the data from 2 time points, 0 minutes and 120 minutes, and using the ranks in the Pearson product-moment correlation formula.
In case of ties, the averaged ranks were used.
|
BL and Weeks 2, 4, 12, and 24
|
Spearman's Rank Correlation Coefficient Between IMPDH Expression and Risk of Infection
Ramy czasowe: BL and Weeks 2, 4, 12, and 24
|
The Spearman's rank correlation coefficient was computed by ranking the data from 2 time points, 0 minutes and 120 minutes, and using the ranks in the Pearson product-moment correlation formula.
In case of ties, the averaged ranks were used.
|
BL and Weeks 2, 4, 12, and 24
|
Spearman's Rank Correlation Coefficient Between IMPDH Expression and Risk of Hematologic Toxicity
Ramy czasowe: BL and Weeks 2, 4, 12, and 24
|
The Spearman's rank correlation coefficient was computed by ranking the data from 2 time points, 0 minutes and 120 minutes, and using the ranks in the Pearson product-moment correlation formula.
In case of ties, the averaged ranks were used.
|
BL and Weeks 2, 4, 12, and 24
|
Spearman's Rank Correlation Coefficient Between IMPDH Expression and Risk of Gastrointestinal Toxicity
Ramy czasowe: BL and Weeks 2, 4, 12, and 24
|
The Spearman's rank correlation coefficient was computed by ranking the data from 2 time points, 0 minutes and 120 minutes, and using the ranks in the Pearson product-moment correlation formula.
In case of ties, the averaged ranks were used.
|
BL and Weeks 2, 4, 12, and 24
|
Spearman's Rank Correlation Coefficient Between MPA Levels and Risk of Infection
Ramy czasowe: BL and Weeks 2, 4, 12, and 24
|
The Spearman's rank correlation coefficient was computed by ranking the data from 2 time points, 0 minutes and 120 minutes, and using the ranks in the Pearson product-moment correlation formula.
In case of ties, the averaged ranks were used.
|
BL and Weeks 2, 4, 12, and 24
|
Spearman's Rank Correlation Coefficient Between MPA Levels and Risk of Hematologic Toxicity
Ramy czasowe: BL and Weeks 2, 4, 12, and 24
|
The Spearman's rank correlation coefficient was computed by ranking the data from 2 time points, 0 minutes and 120 minutes, and using the ranks in the Pearson product-moment correlation formula.
In case of ties, the averaged ranks were used.
|
BL and Weeks 2, 4, 12, and 24
|
Spearman's Rank Correlation Coefficient Between MPA Levels and Risk of Gastrointestinal Toxicity
Ramy czasowe: BL and Weeks 2, 4, 12, and 24
|
The Spearman's rank correlation coefficient was computed by ranking the data from 2 time points, 0 minutes and 120 minutes, and using the ranks in the Pearson product-moment correlation formula.
In case of ties, the averaged ranks were used.
|
BL and Weeks 2, 4, 12, and 24
|
Współpracownicy i badacze
Tutaj znajdziesz osoby i organizacje zaangażowane w to badanie.
Sponsor
Daty zapisu na studia
Daty te śledzą postęp w przesyłaniu rekordów badań i podsumowań wyników do ClinicalTrials.gov. Zapisy badań i zgłoszone wyniki są przeglądane przez National Library of Medicine (NLM), aby upewnić się, że spełniają określone standardy kontroli jakości, zanim zostaną opublikowane na publicznej stronie internetowej.
Główne daty studiów
Rozpoczęcie studiów
1 grudnia 2006
Zakończenie podstawowe (Rzeczywisty)
1 września 2008
Ukończenie studiów (Rzeczywisty)
1 września 2008
Daty rejestracji na studia
Pierwszy przesłany
3 lutego 2011
Pierwszy przesłany, który spełnia kryteria kontroli jakości
8 lutego 2011
Pierwszy wysłany (Oszacować)
9 lutego 2011
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Oszacować)
12 maja 2016
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
8 kwietnia 2016
Ostatnia weryfikacja
1 kwietnia 2016
Więcej informacji
Terminy związane z tym badaniem
Dodatkowe istotne warunki MeSH
- Fizjologiczne skutki leków
- Molekularne mechanizmy działania farmakologicznego
- Środki przeciwinfekcyjne
- Inhibitory enzymów
- Środki przeciwreumatyczne
- Środki przeciwnowotworowe
- Środki immunosupresyjne
- Czynniki immunologiczne
- Środki dermatologiczne
- Środki przeciwbakteryjne
- Antybiotyki, Przeciwnowotworowe
- Środki przeciwgrzybicze
- Środki przeciwgruźlicze
- Antybiotyki, Przeciwgruźlicze
- Inhibitory kalcyneuryny
- Przeciwciała
- Kwas mykofenolowy
- Cyklosporyna
- Cyklosporyny
Inne numery identyfikacyjne badania
- ML19835
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .
Badania kliniczne na mycophenolate mofetil
-
University Hospital, LimogesZakończony
-
University Hospital, ToulouseZakończonyTransplantacja wątrobyFrancja